Alessandra Baldoni

发表

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study

M. Dieci, V. Chiarion-Sileni, V. Zagonel, 2022, European Journal of Cancer.

LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

A. Gadducci, J. Sehouli, N. Colombo, 2020 .

Esophageal stenosis: a differential diagnosis between esophageal cancer and metastasis from other neoplasia.

M. Giovagnoli, P. Marchetti, I. Paris, 2014, Anticancer research.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, T. Park-Simon, 2021, The Lancet. Oncology.

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer

V. Torri, A. Lissoni, M. D’Incalci, 2019, British Journal of Cancer.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.

V. Esposito, V. De Sanctis, G. Minniti, 2013, International journal of radiation oncology, biology, physics.

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells

G. Damia, S. Indraccolo, F. Ricci, 2016, Oncotarget.

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.

S. Mocellin, I. Floriani, C. Aliberti, 2016, Anticancer research.

Cardiac wasting in head and neck cancer and in cardiac autopsies from different cancer types: A study in a chemo‐naïve setting

L. Laurino, G. Azzarello, S. Ausoni, 2023, Journal of cachexia, sarcopenia and muscle.

Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease

M. Rugge, S. Pizzi, M. Fassan, 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer

P. Conte, A. Nieto, V. Alfaro, 2015, Tumori.

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.

I. Floriani, S. Pignata, N. Colombo, 2017, Gynecologic oncology.

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer

V. Torri, E. Mammano, M. O. Nicoletto, 2023, Therapeutic advances in medical oncology.